Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BerGenBio ASA ( (BRRGF) ) has shared an update.
BerGenBio ASA has announced the continuation of its strategic review process, which includes exploring potential sales, mergers, or other strategic transactions, with an expected conclusion by the end of July. The company has also decided to cease all remaining development activities for bemcentinib due to limited financial justification, estimating free cash reserves of NOK 40 – 45 million after closure and settlement of liabilities.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA operates in the biotechnology industry, focusing on the development of innovative cancer therapeutics. The company is known for its work on bemcentinib, a selective AXL inhibitor, although it has now decided to discontinue further development activities for this product.
Average Trading Volume: 489,996
Current Market Cap: NOK69.73M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.